947331-10-4

Basic information

• Product Name: N-Trityl Losartan Carboxylic Acid
• Synonyms: 2-Butyl-4-chloro-1-[[2'-[1-(triphenylmethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxylic Aci;N-Trityl Losartan Carboxylic Acid;2-Butyl-4-chloro-1-[[2'-[1-(triphenylmethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-carboxylic Acid
• CAS NO: 947331-10-4
• Molecular Formula: C₄₁H₃₅ClN₆O₂
• Molecular Weight: 679.21
• Product Categories: Aromatics;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 947331-10-4.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 875.2°C at 760 mmHg
• Flash Point: 483.1°C
• Appearance: /
• Density: 1.25g/cm³
• Vapor Pressure: 9.31E-33mmHg at 25°C
• Refractive Index: 1.664
• CAS DataBase Reference: N-Trityl Losartan Carboxylic Acid(CAS DataBase Reference)
• NIST Chemistry Reference: N-Trityl Losartan Carboxylic Acid(947331-10-4)
• EPA Substance Registry System: N-Trityl Losartan Carboxylic Acid(947331-10-4)

Safety Data

• Hazardous Substances Data: 947331-10-4(Hazardous Substances Data)

Usage

Uses

A Losartan derivative for treatment of hypertension

InChI:InChI=1/C41H35ClN6O2/c1-2-3-23-36-43-38(42)37(40(49)50)47(36)28-29-24-26-30(27-25-29)34-21-13-14-22-35(34)39-44-45-46-48(39)41(31-15-7-4-8-16-31,32-17-9-5-10-18-32)33-19-11-6-12-20-33/h4-22,24-27H,2-3,23,28H2,1H3,(H,49,50)

Upstream product

• 124750-99-8 cozaar 
• 114798-26-4 lorsartan 
• 76-83-5 trityl chloride 
• 124750-92-1 2-butyl-4-chloro-1-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-1H-imidazole-5-carboxylic acid 

Downstream Products

• 947331-26-2 C₄₇H₄₅ClN₆O₅ 
• 947331-18-2 C₄₈H₄₇ClN₆O₅ 
• 947330-97-4 2-butyl-4-chloro-1-[2'-(1H-tetrazol-5-yl) 1,1'-biphenyl-methyl]imidazole-5-carboxylic acid ethyl ester 
• 947331-22-8 2-butyl-4-chloro-1-[(2'-(1-triphenylmethyl-1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl]imidazole-5-carboxylic acid 1-[(isopropoxy)carbonyloxy]methyl ester 
• 947331-24-0 C₄₅H₄₁ClN₆O₅ 
• 947331-12-6 C₄₉H₃₉ClN₆O₄ 
• 947331-16-0 C₄₇H₄₅ClN₆O₅ 
• 947331-15-9 C₄₇H₄₅ClN₆O₄ 
• 947331-20-6 C₅₀H₄₉ClN₆O₅ 
• 947331-14-8 C₄₆H₃₉ClN₆O₅ 
• 1186123-58-9 1-[({[(R)-5-(nitrooxy)hexyl]oxy}carbonyl)oxy]ethyl 2-butyl-4-chloro-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazole-5-carboxylate 
• 1200445-28-8 1-(((3R,3aR,6R,6aR)-6-(5,6-bis(nitrooxy)hexanoyloxy)hexahydrofuro[3,2-b]furan-3-yloxy)carbonyloxy)ethyl 1-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-2-butyl-4-chloro-1H-imidazole-5-carboxylate 
• 1196117-91-5 {[(2-butyl-4-chloro-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methy}-1H-imidazol-5-yl)carbonyl]oxy}acetic acid 
• 1196117-90-4 2-ethoxy-2-oxoethyl 2-butyl-4-chloro-1-{[2'-(1-trityl-1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazole-5-carboxylate 

Relevant articles and documents

A process for preparing a renin - angiotensin - aldosterone system dual inhibitor compound of intermediate

The invention relates to an intermediate compound for preparing RAAS (renin-angiotensin-aldosterone system) dual inhibitor compounds. RAAS dual inhibitors can be used for treating diseases related to an RAAS such as high blood pressure and heart diseases.

ANGIOTENSIN II RECEPTOR ANTAGONISTS

The present invention relates to nitrooxyderivatives of angiotensin II receptor antagonist having the general formula (I): where in R is selected f rom the group consisting of (IIa) - (IIk): when R is selected from (Ilk), Y is selected from the group consisting of: 1) -C(O) (CH2) nR5; 2) -C(O)(CH2n-O-CH2-R5; 3) -C(O)-R6 wherein R6 is the following group: when R is selected from (IIa)-(IIh), Y is selected from the group consisting of: 4) -C(R1R2)OC(O)-(CH2)nR5; 5) -C(R1R2)OC(O)O-(CH2)nR5; 6) C(R1R2)OC(O)(CH2)n-O-CH2-R5; 7) C(R1R2)OC(O)O(CH2)n-O-CH2-R5; 8) -C(R1R2)OC(O)-R6 wherein R6 is as above defined; R1 and R2 are independently selected from the group consisting of hydrogen and C1-4 alkyl; R5 is -CH(ONO2)R7; R7 is CH3 or C1-4 alkyl; n is an integer from 1 to 4; or a pharmaceutically acceptable salt thereof.

Imidazole-5-Carboxylic Acid Derivatives, The Preparation Method Therefor and The Uses Thereof

The invention discloses imidazole-5-carboxylic acid derivatives, and their preparation methods. The derivatives of the invention are Angiotensin II receptor antagonists with angiotensin II antagonistic activity and antihypertensive activity, and thereby can be used as a therapeutical agent to treat hypertension.